Abstract
PI3K signaling is now targeted in first clinical trials in patients with B cell malignancies, including Chronic Lymphocytic Leukemia (CLL), which represent one of the first molecularly targeted therapies for B cell malignancies.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Drug Resistance, Neoplasm*
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
-
Phosphoinositide-3 Kinase Inhibitors*
-
Protein Kinase Inhibitors / administration & dosage*
-
Proto-Oncogene Proteins c-akt / antagonists & inhibitors*
-
TOR Serine-Threonine Kinases / antagonists & inhibitors*
-
Therapies, Investigational / methods*
-
Waldenstrom Macroglobulinemia / drug therapy*
Substances
-
Antineoplastic Agents
-
Phosphoinositide-3 Kinase Inhibitors
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins c-akt
-
TOR Serine-Threonine Kinases